Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984;17(Suppl 1):65S–68S. doi: 10.1111/j.1365-2125.1984.tb02430.x

Interaction between the β-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism

W Kirch, H Spahn, N R Kitteringham, H J Hutt, E Mutschler, E E Ohnhaus
PMCID: PMC1463264  PMID: 6743476

Abstract

1 Neither the kinetics of the hydrophilic β-adrenoceptor blocker atenolol nor those of the lipophilic metoprolol were influenced by the concurrent administration of amitriptyline.

2 Compared with placebo, chronic administration (14 days) of atenolol and metoprolol (each as monotherapy) did not significantly reduce oxidative liver metabolism as measured by antipyrine half-life and by 6-β-hydroxycortisol excretion.

3 Compared with atenolol and metoprolol monotherapy, chronic administration of amitriptyline concurrently with each of the β-adrenoceptor blockers produced an insignificant decrease (circa 10-20%) in antipyrine half-life and 6-β-hydroxycortisol excretion.

4 Amitriptyline appears therefore to have little enzyme-inducing activity.

Keywords: amitriptyline, antipyrine, atenolol, 6-β-hydroxycortisol, metoprolol

Full text

PDF
65S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bax N. D., Lennard M. S., Tucker G. T. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol. 1981 Dec;12(6):779–784. doi: 10.1111/j.1365-2125.1981.tb01306.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Daneshmend T. K., Roberts C. J. The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects. Br J Clin Pharmacol. 1982 Jun;13(6):817–820. doi: 10.1111/j.1365-2125.1982.tb01872.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Greminger P., Vetter H., Boerlin H. J., Baumgart P., Havelka J., Walger P., Lüscher T., Siegenthaler W., Vetter W. Atenolol, Pindolol und Propranolol bei essentieller Hypertonie: ansprechquote und Verträglichkeit. Schweiz Med Wochenschr. 1982 Dec 11;112(50):1831–1835. [PubMed] [Google Scholar]
  4. Henningsen N. C., Mattiasson I. Long-term clinical experience with atenolol--a new selective beta-1-blocker with few side-effects from the central nervous system. Acta Med Scand. 1979;205(1-2):61–66. doi: 10.1111/j.0954-6820.1979.tb06004.x. [DOI] [PubMed] [Google Scholar]
  5. Kirch W., Köhler H., Mutschler E., Schäfer M. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol. 1981 Jan;19(1):65–71. doi: 10.1007/BF00558387. [DOI] [PubMed] [Google Scholar]
  6. Kirch W., Schäfer-Korting M., Axthelm T., Köhler H., Mutschler E. Interaction of atenolol with furosemide and calcium and aluminum salts. Clin Pharmacol Ther. 1981 Oct;30(4):429–435. doi: 10.1038/clpt.1981.184. [DOI] [PubMed] [Google Scholar]
  7. Kirch W., Spahn H., Ohnhaus E. E., Köhler H., Heinz U., Mutschler E. Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. Biopharm Drug Dispos. 1983 Jan-Mar;4(1):73–81. doi: 10.1002/bdd.2510040110. [DOI] [PubMed] [Google Scholar]
  8. Kirk C. A., Cove-Smith R. A comparison between atenolol and metoprolol in respect of central nervous system side effects. Postgrad Med J. 1983;59 (Suppl 3):161–163. [PMC free article] [PubMed] [Google Scholar]
  9. McAinsh J., Holmes B. F., Smith S., Hood D., Warren D. Atenolol kinetics in renal failure. Clin Pharmacol Ther. 1980 Sep;28(3):302–309. doi: 10.1038/clpt.1980.166. [DOI] [PubMed] [Google Scholar]
  10. O'Malley K., Browning M., Stevenson I., Turnbull M. J. Stimulation of drug metabolism in man by tricyclic antidepressants. Eur J Clin Pharmacol. 1973 Aug;6(2):102–106. doi: 10.1007/BF00562435. [DOI] [PubMed] [Google Scholar]
  11. Ohnhaus E. E., Kirchhof B., Peheim E. Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin. Clin Pharmacol Ther. 1979 May;25(5 Pt 1):591–597. doi: 10.1002/cpt1979255part1591. [DOI] [PubMed] [Google Scholar]
  12. Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979 Mar 26;15(2):139–145. doi: 10.1007/BF00609878. [DOI] [PubMed] [Google Scholar]
  13. Schäfer-Korting M., Kirch W., Axthelm T., Köhler H., Mutschler E. Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther. 1983 Mar;33(3):283–288. doi: 10.1038/clpt.1983.34. [DOI] [PubMed] [Google Scholar]
  14. Schäfer M., Mutschler E. Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms. J Chromatogr. 1979 Feb 1;169:477–481. doi: 10.1016/0021-9673(75)85087-4. [DOI] [PubMed] [Google Scholar]
  15. Schäfer M., Mutschler E. Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms. J Chromatogr. 1979 Oct 11;164(2):247–252. doi: 10.1016/s0378-4347(00)81195-0. [DOI] [PubMed] [Google Scholar]
  16. Tucker G. T., Bax N. D., Lennard M. S., Crewe K., Woods H. F. Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol. 1982 Nov;14(5):743–744. doi: 10.1111/j.1365-2125.1982.tb04967.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES